In conclusion, our study suggests that responders to BRAF/MEK-targeted therapy in metastatic melanoma harbor a distinct gut microbiota profile enriched in previously described immune-modulating taxa such as Lachnospiraceae, Coriobacteriaceae, Adlercreutzia and Prevotellaceae. This evidence concerns the gene BRAF and metastatic melanoma.